Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver disease. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and gain-of-function drug therapy, to meet the urgent need for treatments that have the potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today. Ambys was launched in 2018 by Third Rock Ventures and Takeda Pharmaceuticals with $140M in starting capital and is headquartered in South San Francisco, Calif.
Location: United States, California, Redwood City
Employees: 51-200
Total raised: $187M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | Takeda Ven... | takeda.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 21.12.2021 | Series A | $47M | - |
| 08.08.2018 | Series A | $140M | Takeda Ven... |
Mentions in press and media 5
| Date | Title | Description |
| 13.12.2018 | Third Rock, Takeda-backed Ambys ushers in ex-NGM Bio president Jeff Jonker as CEO | Trained as a lawyer, Jeff Jonker has a lot in common with Merck’s Ken Frazier, who was in charge of defending Merck’s controversial Vioxx in the courts before rising to the post of CEO in 2011. Jonker — part of the executive t... |
| 12.08.2018 | Ambys Medicines Raises $60M Series A from Third Rock Ventures | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Ambys Medicines, a company founded to capitalize on advances in liver biology and regenerative medicines to develop therapies for serious liver diseases, launched today with a $60 million Series A fina... |
| 10.08.2018 | Term Sheet — Friday, August 10 | MORE DEBT Happy Friday, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop According to the WSJ, the note, which accrues interest of 2.8% a year starting next September, gives WeWork the ability to foc... |
| 08.08.2018 | Liver-focused Ambys launches with $140M, Takeda partnership | Third Rock Ventures is debuting Ambys Medicines, which will develop cell and gene therapies as well as drugs for chronic liver diseases. Ambys starts life with $140 million in committed capital, including $100 million from Takeda, part of w... |
| 08.08.2018 | Ambys Medicines Launches with $140M in Funding | Ambys Medicines, a Redwood City, CA-based developer of regenerative medicine therapies for serious liver diseases, raised $60m in Series A financing. Backers included Third Rock Ventures and Takeda. As part of the launch, Ambys also announc... |